405 related articles for article (PubMed ID: 11389076)
1. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
2. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
[TBL] [Abstract][Full Text] [Related]
4. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase as a new target for cancer chemotherapy.
Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
[TBL] [Abstract][Full Text] [Related]
6. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
7. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Kano M; Yamada S; Hoshino I; Murakami K; Akutsu Y; Sakata H; Nishimori T; Usui A; Miyazawa Y; Kamada T; Tsujii H; Matsubara H
Anticancer Res; 2009 Nov; 29(11):4433-8. PubMed ID: 20032389
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
Charrier C; Bertrand P; Gesson JP; Roche J
Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
13. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
14. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
15. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
16. Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from alpha-tubulin sequence.
Jose B; Okamura S; Kato T; Nishino N; Sumida Y; Yoshida M
Bioorg Med Chem; 2004 Mar; 12(6):1351-6. PubMed ID: 15018907
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
[TBL] [Abstract][Full Text] [Related]
18. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
19. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
[TBL] [Abstract][Full Text] [Related]
20. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors.
Nishino N; Jose B; Shinta R; Kato T; Komatsu Y; Yoshida M
Bioorg Med Chem; 2004 Nov; 12(22):5777-84. PubMed ID: 15498654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]